247 related articles for article (PubMed ID: 20567921)
1. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
[TBL] [Abstract][Full Text] [Related]
2. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
[TBL] [Abstract][Full Text] [Related]
4. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
7. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
[TBL] [Abstract][Full Text] [Related]
8. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
[TBL] [Abstract][Full Text] [Related]
9. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
10. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
[TBL] [Abstract][Full Text] [Related]
11. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Walter H; Thomas AL
Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
[No Abstract] [Full Text] [Related]
12. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
[TBL] [Abstract][Full Text] [Related]
13. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
[TBL] [Abstract][Full Text] [Related]
14. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
[TBL] [Abstract][Full Text] [Related]
15. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
16. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
[TBL] [Abstract][Full Text] [Related]
17. Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
Faron M; Chirica M; Tranchard H; Balladur P; de Gramont A; Afchain P; Andre T; Paye F
J Gastrointest Cancer; 2014 Sep; 45(3):298-306. PubMed ID: 24610400
[TBL] [Abstract][Full Text] [Related]
18. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
